Gilead wins Zydelig OK, but Pharmacyclics scores
This article was originally published in Scrip
Executive Summary
While it was Gilead Sciences that won the earlier-than-expected triple US approval on 23 July for its targeted oral phosphoinositide 3-kinase delta inhibitor Zydelig (idelalisib), it was the company's expected competitor Pharmacyclics that scored – with shares of the latter firm climbing 11%, likely on the black-box warning about liver toxicity and other concerns the FDA imposed on the former manufacturer's new drug.